Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

11/12/24 9:50:12 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALNY alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.21 ALNYLAM PHARMACEUTICALS INC COMMON STOCK Cusip #02043Q107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #02043Q107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 14,360,932 Item 6: 0 Item 7: 14,755,604 Item 8: 0 Item 9: 14,755,604 Item 11: 11.484% Item 12: HC Cusip #02043Q107 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 14,755,604 Item 8: 0 Item 9: 14,755,604 Item 11: 11.484% Item 12: IN Item 1(a). Name of Issuer: ALNYLAM PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 675 West Kendall Street, Henri A. Termeer Square Cambridge, MA 02142 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 02043Q107 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 14,755,604 (b) Percent of Class: 11.484% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 14,755,604 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ALNYLAM PHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of ALNYLAM PHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Diversifying Solutions LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ALNYLAM PHARMACEUTICALS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $ALNY alert in real time by email

Recent Analyst Ratings for

$ALNY

Date	Price Target	Rating	Analyst
3/31/2025	$353.00	Buy	Redburn Atlantic
3/24/2025	$280.00 → $328.00	Neutral → Overweight	Analyst
11/12/2024		Peer Perform → Underperform	Wolfe Research
10/16/2024		Sector Outperform	Scotiabank
8/16/2024	$198.00 → $370.00	Neutral → Buy	Goldman
2/16/2024	$173.00	Buy → Neutral	Goldman
2/15/2024		Peer Perform	Wolfe Research
12/8/2023	$171.00	Equal Weight	Wells Fargo

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Alnylam Pharmaceuticals Inc.

Chat with this insight

Recent Analyst Ratings for $ALNY

$ALNY Press Releases

Fastest customizable press release news feed in the world

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

Alnylam Issues 2024 Corporate Responsibility Report

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

$ALNY Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Redburn Atlantic initiated coverage on Alnylam Pharma with a new price target

Alnylam Pharma upgraded by Analyst with a new price target

Alnylam Pharma downgraded by Wolfe Research

$ALNY Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Bonney Michael W exercised 11,250 shares at a strike of $131.21 and sold $3,124,217 worth of shares (11,250 units at $277.71) (SEC Form 4)

Chief Executive Officer Greenstreet Yvonne gifted 8,376 shares, decreasing direct ownership by 15% to 48,948 units (SEC Form 4)

Director Ausiello Dennis A was granted 775 shares, increasing direct ownership by 570% to 911 units (SEC Form 4)

$ALNY FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

FDA Approval for OXLUMO issued to ALNYLAM PHARMS INC

FDA Approval for AMVUTTRA issued to ALNYLAM PHARMS INC

$ALNY SEC Filings

Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

SEC Form 10-Q filed by Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ALNY Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Reitan Colleen F bought $10,363 worth of shares (36 units at $287.85), sold $8,383 worth of shares (36 units at $232.86) and was granted 775 shares (SEC Form 4)

$ALNY Large Ownership Changes

This live feed shows all institutional transactions in real time.